Applied Biosciences Corp.

Equities

APPB

US03815L1026

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:30:19 23/10/2023 BST			5-day change	1st Jan Change
0.0002 ^USD	-.--%		-.--%	-.--%

2020	Applied BioSciences Corp. Terminates Agreement to Offer Test Kits	CI
2020	Applied BioSciences Begins Offering Coronavirus Test Kit to the General Public to Combat Spread of COVID-19	CI

Applied Biosciences Corp. Reports Earnings Results for the Second Quarter Ended September 30, 2019

November 14, 2019 at 06:33 pm

Applied Biosciences Corp. announced earnings results for the second quarter ended September 30, 2019. For the second quarter, the company announced total revenue was USD 244,274 compared to USD 48,966 a year ago. Operating loss was USD 820,847 compared to USD 293,171 a year ago. Net loss was USD 777,746 compared to USD 110,423 a year ago. Basic loss per share was USD 0.06 compared to USD 0.01 a year ago. For the half year, total revenue was USD 455,731 compared to USD 59,400 a year ago. Operating loss was USD 1.302 million compared to USD 851,978 a year ago. Net loss was USD 1.201 million compared to USD 505,924 a year ago. Basic loss per share was USD 0.09 compared to USD 0.05 a year ago.

Latest news about Applied Biosciences Corp.

Applied BioSciences Corp. Terminates Agreement to Offer Test Kits	24/04/20	CI
Applied BioSciences Begins Offering Coronavirus Test Kit to the General Public to Combat Spread of COVID-19	31/03/20	CI
Applied Biosciences Corp. Announces Resignation of Raymond Urbanski as Chief Executive Officer and Director	19/03/20	CI
Applied Biosciences Corp. Reports Earnings Results for the Third Quarter Ended December 31, 2019	18/02/20	CI
Applied Biosciences Corp. Reports Earnings Results for the Second Quarter Ended September 30, 2019	14/11/19	CI
Pond Naturals Signs Agreement with Applied BioSciences to Sell its X10 Pet Supplement in the US alongside CBD-based Herbal Pet products	17/10/19	CI
Applied Biosciences Corp. Appoints Michael Beaubaire as Director	07/10/19	CI
Applied BioSciences Corp. Announces Resignation of John Brady as Director	16/09/19	CI
Applied Biosciences Corp. announced that it has received $0.25 million in funding from FirstFire Capital Management LLC	08/09/19	CI
Applied Biosciences Corp. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	03/09/19	CI
Applied Biosciences Corp. Reports Earnings Results for the First Quarter Ended June 30, 2019	14/08/19	CI
Applied Biosciences Corp. Reports Earnings Results for the Full Year Ended March 31, 2019	01/07/19	CI
Applied Biosciences Corp. Auditor Raises 'Going Concern' Doubt	30/06/19	CI
Applied BioSciences Launches Champ Organics CBD Product Line	06/06/19	CI
Applied Biosciences Corp. Appoints Raymond Urbanski as Chief Executive Officer and Director	28/05/19	CI
Applied BioSciences Corp. Appoints Raymond W. Urbanski as Chief Executive Officer	07/05/19	CI
Applied Biosciences Corp. Appoints Scott Stevens as Director	19/04/19	CI
Applied BioSciences Announces Partnership with Boxing Heavyweight Champion Shannon Briggs	20/03/19	CI
Applied Biosciences Corp. Reports Revenue Results for the Third Quarter of 2019	18/03/19	CI
Applied Biosciences Corp. Reports Earnings Results for the Third Quarter Ended December 31, 2018	13/02/19	CI
Xiang-Qun Xie Joins Applied Biosciences Corp.'s Scientific Advisory Board	24/01/19	CI
Applied Biosciences Corp. acquired an unknown majority stake in Trace Analytics for $1.25 million.	08/01/19	CI
Applied Biosciences Corp. Enters Vape Inhaler Market	07/11/18	CI
Applied Biosciences Corp Expands Product Line and Launches Hemp-Derived CBD Product Pet Line Under the HerbalPet Brand	22/10/18	CI
Applied Biosciences Corp. announced that it expects to receive $1 million in funding from Triton Funds LLC	14/10/18	CI

Chart Applied Biosciences Corp.

Duration

Period

More charts

Company Profile

Applied BioSciences Corp. is a vertically integrated company that is focused on the development of science-driven cannabinoid therapeutics/biopharmaceuticals. The Company delivers cannabidiol (CBD) products as well as testing and analytics capabilities to its customers. It sells consumer products, including health and wellness creams, tinctures, edibles, confections, clothing, apparel, and other various branded products. Its various brands include Remedi, Remedi Plus, HerbalPet, Champ Organics and Equine Care. Its products are focused on the medical, bioceutical and pet health industries. The Company's subsidiaries include Applied Products LLC, Trace Analytics, Inc., and API Holdings, LLC, among others.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
APPLIED BIOSCIENCES CORP.	-.--%	4.28K
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research